We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has BioLife Solutions, Inc. (BLFS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
BioLife Solutions, Inc. is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BioLife Solutions, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for BLFS' full-year earnings has moved 23.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BLFS has moved about 45.4% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 8.1% on a year-to-date basis. As we can see, BioLife Solutions, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Eli Lilly (LLY - Free Report) . The stock has returned 57.5% year-to-date.
In Eli Lilly's case, the consensus EPS estimate for the current year increased 3.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, BioLife Solutions, Inc. is a member of the Medical - Products industry, which includes 88 individual companies and currently sits at #72 in the Zacks Industry Rank. On average, this group has gained an average of 16.4% so far this year, meaning that BLFS is performing better in terms of year-to-date returns.
Eli Lilly, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 12-stock industry is ranked #34. The industry has moved +20.5% so far this year.
Investors interested in the Medical sector may want to keep a close eye on BioLife Solutions, Inc. and Eli Lilly as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has BioLife Solutions, Inc. (BLFS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
BioLife Solutions, Inc. is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BioLife Solutions, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for BLFS' full-year earnings has moved 23.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BLFS has moved about 45.4% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 8.1% on a year-to-date basis. As we can see, BioLife Solutions, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Eli Lilly (LLY - Free Report) . The stock has returned 57.5% year-to-date.
In Eli Lilly's case, the consensus EPS estimate for the current year increased 3.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, BioLife Solutions, Inc. is a member of the Medical - Products industry, which includes 88 individual companies and currently sits at #72 in the Zacks Industry Rank. On average, this group has gained an average of 16.4% so far this year, meaning that BLFS is performing better in terms of year-to-date returns.
Eli Lilly, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 12-stock industry is ranked #34. The industry has moved +20.5% so far this year.
Investors interested in the Medical sector may want to keep a close eye on BioLife Solutions, Inc. and Eli Lilly as they attempt to continue their solid performance.